

United States are presented. There is a need for both the FDA and the industry to change their practices, if we, in the United States, are able to catch up with the spread of biosimilars in Europe.

Bibliography

1. <http://www.bioprocessintl.com/wp-content/uploads/2018/01/16-1-Biosimilars-eBook.pdf?submissionGuid=ba89dcc5-a456-4ef0-849d-bceda94f16a3>
2. <https://www.europeanpharmaceuticalreview.com/article/70987/obstacles-success-biosimilars-us-market/>